company background image
STX logo

Shield Therapeutics AIM:STX Stock Report

Last Price

UK£0.02

Market Cap

UK£15.8m

7D

-5.8%

1Y

-66.0%

Updated

28 Mar, 2024

Data

Company Financials +

Shield Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shield Therapeutics
Historical stock prices
Current Share PriceUK£0.02
52 Week HighUK£0.13
52 Week LowUK£0.019
Beta0.93
1 Month Change-16.32%
3 Month Change-69.78%
1 Year Change-65.97%
3 Year Change-95.29%
5 Year Change-97.32%
Change since IPO-98.71%

Recent News & Updates

Recent updates

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Shareholder Returns

STXGB PharmaceuticalsGB Market
7D-5.8%4.8%2.3%
1Y-66.0%2.5%2.7%

Return vs Industry: STX underperformed the UK Pharmaceuticals industry which returned 2.5% over the past year.

Return vs Market: STX underperformed the UK Market which returned 2.7% over the past year.

Price Volatility

Is STX's price volatile compared to industry and market?
STX volatility
STX Average Weekly Movement15.8%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: STX's share price has been volatile over the past 3 months.

Volatility Over Time: STX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
200827Greg Madisonhttps://www.shieldtherapeutics.com

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Shield Therapeutics plc Fundamentals Summary

How do Shield Therapeutics's earnings and revenue compare to its market cap?
STX fundamental statistics
Market capUK£15.84m
Earnings (TTM)-UK£38.73m
Revenue (TTM)UK£5.86m

2.7x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
STX income statement (TTM)
RevenueUS$7.40m
Cost of RevenueUS$4.08m
Gross ProfitUS$3.31m
Other ExpensesUS$52.19m
Earnings-US$48.88m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.063
Gross Margin44.77%
Net Profit Margin-660.88%
Debt/Equity Ratio21.1%

How did STX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.